Abbott’s Industry-Leading AMPLATZER Line1
Abbott’s Amplatzer line not only pioneered structural heart defect occluders. It also retains a leadership position in structural heart innovation and treatment worldwide.1
Ventricular septal defects (VSDs) are the most common congenital heart defect, and Amplatzer Muscular as well as Membranous VSD Occluders have a 20-year record of safety and effectiveness.2
Abbott offers 3 devices for percutaneous, transcatheter VSD occlusion. Like many Amplatzer occluders, these devices:
- Are self-expandable, double-disc devices
- Are made from Nitinol wire mesh
- Can be recaptured and redeployed for precision in placement
- Are designed for complete closure
- Provide substrate for tissue in-growth
- Have a connecting waist that corresponds to the size of the VSD*
* With the condition that the implanter chooses the appropriate device size
AP2947052-WBO Rev. A
- Data on file at Abbott.
- Stout KK, et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;000:e000-e000. doi: 10.1161/CIR.0000000000000603.
- Warnes CA, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;52:e143–e263.